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Pheochromocytomas, uncommon adrenal tumors, have an uncertain behavior. Re-
cently, PASS criteria were proposed for differentiating between benign and malig-
nant cases. These are not perfect, however. The aim of the study was to investigate
angiogenesis and mast cell density in context of the clinical behavior and morpho-
logic characteristics of pheochromocytomas.
Mean intratumoral chymase positive cell count was 14.50 for malignant, 15.73 for
benign cases; mean subcapsular chymase positive cell count was 12.50 for malignant,
11.27 for benign cases. Mean intratumoral tryptase positive cell count was 17.50 for
malignant and 17.91 for benign cases; mean subcapsular tryptase positive cell count
was 15.25 for malignant and 15.73 for benign cases. Mean intratumoral CD31 pos-
itive vessel count was 46.98 for malignant and 51.02 for benign cases; mean sub-
capsular CD31 positive vessel count was 44.86 for malignant and 39.81 for benign
cases. Mean intratumoral CD105 positive vessel count was 37.84 for malignant and
35.95 for benign cases; mean subcapsular CD105 positive vessel count was 26.36
for malignant and 22.03 for benign cases. The differences between benign and ma-
lignant cases were not significant. All the vascular counts were correlated with mast
cells counts. PASS index was inversely correlated with mast cell counts.
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Introduction
Pheochromocytomas are rare tumors arising from
sympathochromaffin cells of adrenal medulla. The same
tumors deriving from chromaffin cells in extraadren-
al locations are called paragangliomas (extraadrenal
pheochromocytomas). Most of pheochromocytomas be-
have in a benign fashion; the prevalence of malignan-
cy ranges from 2.5% to 25% of cases [1]. The distinction
between malignant and benign pheochromocytomas
was traditionally regarded as particularly difficult. The
only valid criterion was a clinically detectable metas-
tasis, defined as the presence of tumor cells in sites where
chromaffin cells are normally absent or recurrent dis-
ease [1-3]. Indeed this remains a difficult issue; to aid
this, several scoring systems were created. These sys-
tems used local invasion, histological growth patterns,
cytological features or mitotic activity as criteria for as-
sessing the risk of malignant behavior. Currently, the
most widely used multifactorial histological system is
PASS proposed by Thompson [4]. It seems to show fair-
ly good performance, nevertheless no current score sys-
tem predicts aggressive behavior unequivocally [5]. As
a consequence, lifelong follow-up is necessary in all cas-
es to assure early detection and treatment of metastases.
This leads to excessive health system expenses and un-
necessary anxiety of patients.
Angiogenesis is essential for tumor growth and
metastasis formation. It is assumed that cancers, after
an early vasculogenic phase, acquire ability to induce
new vessels formation, this is followed by accelerated
growth and clinically apparent tumor. Such phenom-
enon is referred to as angiogenic switch. Angiogenic
switch depends on the ability to release specific growth
factors stimulating blood vessels formation as well as
down-regulation of inhibitors. The source of those fac-
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tors is both neoplastic cells and various stromal and im-
mune cells, like macrophages and mast cells. Although
mast cells are not the most numerous cell population
of tumor stroma, they produce a plethora of pro-an-
giogenic and tissue-remodeling factors. They may thus
participate in tumor growth stimulation, tumor
growth inhibition, angiogenesis as well as antitumor
immune response. As a consequence, depending on the
tumor type and location within the tumor, mast cells
density may show a positive or negative correlation with
tumor progression [6]. What is more, mast cells do not
constitute a homogenous population, as their two main
subsets, chymase-positive and tryptase-positive ones
may have different functions.
Angiogenesis is a complex phenomenon, therefore
many strategies are used to evaluate its role in tumor
progression. For a pathologist, the most standard group
of methods consists of assessing microvessel density
(MVD), total microvascular area, vascular patterns and
expression of angiogenic factors to assess their diagnostic
and prognostic significance [7, 8]. Still, the overall sig-
nificance of angiogenesis remains incompletely un-
derstood. In some cancers, like breast cancer, tumors
with a more extensive vascular network behave more
aggressively, while in other, like renal cell carcinoma,
the relationship is inverse. What is more, most stud-
ies of angiogenesis deal with highly aggressive, com-
mon cancers [9].
The aim of our study was to investigate the num-
ber of tryptase-positive and chymase-positive mast cells,
density of CD31-positive and CD105-positive blood ves-
sels and to correlate these findings with morphologic
parameters and clinical behavior in adrenal pheochro-
mocytomas. In particular, we wanted to verify whether
any of the vascular- or mast cell-related parameters was
related to the malignant clinical course.
Material and methods
The material consisted of 15 pheochromocytomas
found in the files of the Department of Pathomor-
phology UJCM in Cracow. The material was fixed in
formalin, routinely processed and paraffin embedded.
All cases were reevaluated by a pathologist experienced
in adrenal pathology (MB). PASS score was assessed
as defined by Thompson [4]. Clinical data were derived
from patients’ records; malignant behavior was defined
as formation of metastases or local tumor recurrence.
In each case, a single section including well-preserved
tumor tissue as well as tumor capsule were chosen. From
the tissue blocks, 3 µm sections were prepared.
Immunohistochemistry was performed by a standard
method. Briefly, the slides were dewaxed, rehydrated
and incubated in 3% peroxide solution for 10 minutes
to block endogenous peroxidase activity. Antigen re-
trieval was carried out by microwaving in citrate buffer
(pH 6.0) for 5 minutes at 700 W, then for 5 minutes
at 600 W for chymase stain and by trypsin digestion
(30 min at 37°C) for tryptase stain. Primary antibod-
ies are listed in Table I. The LabVision (Thermo Fish-
er Scientific, USA) detection system was used. 3-amino-
9-ethylcarbasole served as the chromogen. The slides
were counterstained with Mayer’s hematoxylin (DAKO,
Denmark).
For assessment of the immunohistochemistry, the
subcapsular space was defined as the area within one
high power field (0.5 mm) beneath the tumor outer bor-
der, and the remainder of the tumor as intratumoral
space. Tryptase-positive mast cells and chymase-pos-
itive mast cells were counted both in peri- and intra-
tumoral space using an Olympus BX51 microscope
equipped with a 40× UPlanFLN eyepiece (field of view
diameter 0.55 mm). For each parameter, 10 high pow-
er fields were assessed. The results were expressed as
a number of cells per square millimeter. For assessment
of the microvessel density, morphologically identifiable
vessels, collections of immunopositive cells as well as
single endothelial cells were counted. For each pa-
rameter, 10 high power fields were assessed. For sub-
capsular count these were consecutive fields, while for
intratumoral count a pre-scanning was done on low
magnification to choose an area with the highest vas-
cular density (‘hot spot’). The results were expressed
as a number of cells per square millimeter.
Statistical analysis was performed using Statistica
10 (StatSoft Inc., USA). The comparison between
groups was done with Mann-Whitney U test; the re-
lationship between variables was assessed using Spear-
man’s correlation coefficient. The significance level was
set at 0.05.
Results
The material under study consisted of 15 cases of
adrenal pheochromocytomas. There were 10 females
and 5 males. The age of the patients ranged from 28
to 73 years (mean 56.2, SD 18.5). Males were slight-
ly older than women (56.2 vs. 50.2) but this difference
did not reach statistic significance. Eleven tumors were
located at the right side, 3 at the left and in one case
laterality was not stated. Two patients fulfilled the cri-
teria for neurofibromatosis type I. The tumor diame-
ter ranged from 2.5 to 13 cm (mean 4.85, SD 2.74).
The tumor diameter was inversely correlated to age of
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Table I. Primary antibodies used in the study
SPECIFICITY CLONE MANUFACTURER DILUTION
CD31 JC70A DAKO 1 : 20
CD105 4G11 Novocastra 1 : 50
Chymase CC1 Abcam 1 : 100
Tryptase AA1 Novocastra 1 : 100
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the patients (R = –0.21) but this relationship was not
statistically significant.
In 4 cases, malignant behavior was observed; these in-
cluded one local relapse, one tumor spreading to the bone,
lung and liver, one with liver metastases and one with
metastases to contralateral adrenal. Patients with ma-
lignant tumors were somewhat younger (45.5 vs. 54.64)
but this was not statistically significant. Malignant tu-
mors were larger (average 8.13 cm vs. 3.66 cm) and this
difference was statistically significant (U = 1.5, p < 0.01).
The mitotic count ranged from 0 to 40/10 HPF (mean
4.26, SD 10.26). Mitotic figures were much more nu-
merous in malignant lesions (14 vs. 0.72) and this dif-
ference was statistically significant (U = 3.0, p < 0.011).
Mitotic activity was positively correlated with the tu-
mor diameter (R = 0.62, p < 0.015), but this rela-
tionship becomes insignificant if stratified into a be-
nign and malignant group. It may be noticed however
that in a malignant group an inverse relationship was
present (R = –0.32) while benign tumors showed pos-
itive one (R = 0.28). The PASS index ranged from 1
to 11 (average 3.93, SD 3.55). Obviously, the PASS
index was higher in the malignant group (9.25 vs. 2.0).
The number of chymase- and tryptase-positive cells
is shown in Table II, and the vessel counts in Table III.
No significant differences in these parameters were ob-
served between benign and malignant tumors, neither
with the sex of the patient nor laterality (Fig. 1, 2).
Age of the patients was inversely correlated with all
mast cells’ and vascular counts, with the strongest re-
lationship with intratumoral chymase-positive cells
(R = –0.39). The tumor diameter was positively cor-
related with all mast cell counts, but only a relation-
ship to subcapsular chymase-positive cells was statis-
tically significant (R = 0.55, p < 0.04). For mitotic
index, the strongest positive correlate was intratumoral
CD105-positive vessel count (R = 0.35), while stron-
gest negative was subcapsular tryptase-positive cells
(R = –0.32). PASS index was inversely correlated with
all mast cell counts, with intratumoral tryptase-posi-
tive cells being the strongest (R = 0.45). These cor-
relations were even stronger and more significant if only
benign category was analyzed, with the exception of
the PASS index. Because of the small number of cas-
es, we did not further analyze the correlations in the
malignant group.
All the vascular counts were positively correlated with
mast cells counts, although the correlation coefficient
varied greatly; the highest and most significant were
the correlations between subcapsular chymase-positive
cells and subcapsular CD31-positive vessels count
(R = 0.61, p < 0.016), subcapsular tryptase-positive
cells and subcapsular CD31-positive vessels count
(R = 0.53, p < 0.044) and subcapsular tryptase-pos-
itive cells and intratumoral CD31-positive vessels count
(R = 0.52, p < 0.46). Again, most of these relation-
ships were retained if only benign tumors were analyzed.
Discussion
Angiogenesis is a prerequisite for the growth, in-
vasion and metastasis of solid tumors including
pheochromocytomas. One of the most potent induc-
ers of new blood vessels formation is hypoxia. There
are data pointing to the central role of hypoxia path-
way activation in pheochromocytoma tumorigenesis
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Table II. Counts of chymase- and tryptase-positive mast cells
CHYMASE TRYPTASE
INTRATUMORAL SUBCAPSULAR INTRATUMORAL SUBCAPSULAR
MEAN SD MIN MAX MEAN SD MIN MAX MEAN SD MIN MAX MEAN SD MIN MAX
mali- 14.50 5.26 7.00 19.00 12.50 4.36 9.00 18.00 17.50 7.68 6.00 22.00 15.25 11.87 1.00 30.00
gnant
benign 15.73 14.20 0.00 39.00 11.27 14.67 0.00 50.00 17.91 18.65 3.00 64.00 15.73 16.82 0.00 57.00
all cases 15.40 12.26 0.00 39.00 11.60 12.57 0.00 50.00 17.80 16.16 3.00 64.00 15.60 15.24 0.00 57.00
SD stands for standard deviation
Table III. Counts of CD31- and CD105-positive vessels
CD31 CD105
INTRATUMORAL SUBCAPSULAR INTRATUMORAL SUBCAPSULAR
MEAN SD MIN MAX MEAN SD MIN MAX MEAN SD MIN MAX MEAN SD MIN MAX
mali- 46.98 15.30 36.56 69.73 44.86 14.70 31.46 65.48 37.84 14.67 25.51 56.97 26.36 4.45 20.41 29.76
gnant
benign 51.02 17.62 27.21 79.08 39.81 14.11 20.41 64.63 35.95 13.49 14.46 59.52 22.03 12.12 0.00 40.82
all cases 49.94 16.60 27.21 79.08 41.16 13.92 20.41 65.48 36.45 13.30 14.46 59.52 23.19 10.63 0.00 40.82
SD stands for standard deviation
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[10]. Indeed, some von Hippel-Lindau patients develop
pheochromocytomas [11]. The expression of markers
associated with angiogenesis has been studied in be-
nign and malignant pheochromocytomas and para-
gangliomas [12]. The expression of vascular en-
dothelial growth factor (VEGF) and hypoxia inducible
factor 1α (HIF-1α) within tumor cells was demonstrated
in experimental models and in human tissue. Increased
expression of VEGF and HIF-1α was noted in malig-
nant pheochromocytomas while benign counterparts
showed only a weak expression. Increased expression
of VEGF was associated with decreased metastasis-
free survival [13-15]. Expression of VEGF cannot be
used alone as an indicator of malignancy, though
[10, 13]. Additionally, the genetic status of the patient
may influence the VEGF overexpression. Indeed, two
different types of pheochromocytoma have been defined
by gene expression profiling [10]. Cluster 1 compris-
es cases associated with hypoxic signature such as suc-
cinate dehydrogenase genes (SDHx) and von Hippel-
Lindau (VHL) gene-related tumors. Cluster 2 includes
tumors with RET proto-oncogene, NF-1 (neurofibro-
matosis 1) and TMEM127 (transmembrane protein
127) genes germline mutations as well as most sporadic
tumors [16]. In cluster 1, overexpression of angiopo-
etin 2, HIF-2α, VEGF in tumor cells and vascular en-
dothelial growth factor receptor-1 and 2 (VEGFR-1 and
VEGFR-2) in endothelium was observed in both ma-
lignant and benign pheochromocytomas.
The microvessel density (MVD) has been suggest-
ed to be an adverse prognostic indicator for a wide range
of tumors such as breast, gastrointestinal, lung, hepatic
and urogenital cancers [17]. However, data concern-
ing angiogenesis and prognosis are not fully consistent.
There are reports where MVD was not correlated with
intratumoral endothelial cell and tumor cell prolifer-
ation [18]. In non-small-cell lung carcinoma high MVD
is inversely correlated with the risk of distant metas-
tases [19]. In renal cell carcinoma, even an inverse re-
lationship between MVD and patient survival has been
observed [20]. That result could depend on intrinsic
differences in tumor biology, but could be partly due
to the different techniques and antibodies used to quan-
tify tumor blood vessels [7, 21, 22]. The choice of the
antibody (e.g. CD34, CD31, von Willebrand factor,
or CD105) used to detect endothelial cells of the tu-
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Fig. 1. The values of vascular and mast cells’ parameters split between malignant and benign pheochromocytomas.
Intratumoral values are shown on the left, subcapsular on the right. The central point is the mean, the box represents
standard error and whiskers/asterisk – standard deviation





































mor microvasculature certainly influences the study re-
sults, as does the method of measuring vessels densi-
ty [17]. Selection of a particular area of the tumor for
MVD assessment may also play a role. Vascular den-
sity is not homogenous throughout the tumor. It has
been suggested that the angiogenesis deep inside the
tumor is related more to remodeling and migration of
endothelial cells while most robust endothelial prolif-
eration occurs at the tumor periphery [23]. In early re-
ports on angiogenesis in pheochromocytomas, the num-
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Fig. 2. CD31-positive vessels in benign (A) and malignant (B) pheochromocytoma (top panel), chymase-positive cells in
benign (C) and malignant (D) pheochromocytoma (middle panel) and tryptase-positive cells in benign (E) and malignant





ber of blood vessels correlated with the invasive behavior
[24]. Feng [14], Zielke [15] and Roojens [25] have ob-
served a significantly greater number of blood vessels
in metastasizing tumors. However, other authors did
not confirm these results [13, 26, 27].
In the present study, we used anti-CD31 antibody
because of its relative specificity for blood vessel en-
dothelia [22]. The other marker studied was endoglin
(CD105) that is preferentially expressed in the activated
endothelia. Choice of such markers should allow for
a better characterization of the angiogenic process [7,
28]. CD31 and CD105-positive vessels were counted
in the inner tumor area and at the tumor periphery.
Our study did not reveal any significant difference in
MVD between malignant and benign groups regard-
less of the tumor area. This may be due to the limit-
ed number of analyzed cases, especially of the less com-
mon malignant ones.
Microvessel density not necessarily correlates with
angiogenic dependence of a tumor. It has been recently
shown that overall vascular density in prostatic carci-
noma is identical to the normal organ; this analysis was
based on evaluation of the overall number of tumor ves-
sels, while the previous studies showing increased MVD
were done using the standard ‘hot spot’ method [9].
The method of microvessels’ counting may thus in-
troduce a significant bias. The MVD for human lung,
mammary, renal cell, colon carcinomas, as well as
glioblastomas or pituitary adenomas are lower than
those of their normal tissue counterparts; yet the mi-
crovessel density influences the survival [6]. Indeed, the
relative paucity of the vascular network in tumors may
make angiogenesis the limiting factor in tumor
growth. What is more, the crude number of vessels not
necessarily reflects the blood supply to the tumor. The
tumor-related microvessels are often poorly formed, tor-
tuous and the blood flow may be inefficient, slow or
even reversed [29-31]. Lately, it has been proposed that
all cancers could be characterized as bearing a prolif-
erative or a tissue remodeling phenotype [32]. If such
classification holds, it may explain some of the incon-
sistencies in angiogenesis studies. The density of
blood vessels within a tumor might, to some degree,
reflect its metabolic demand [17]. The correlation be-
tween mitotic activity and CD105 vessel count found
in our study may support such hypothesis.
Angiogenesis is an extremely complex process.
Many humoral and cellular mechanisms are involved
in its initiation and regulation. The microcirculation
of tumors can be heterogeneous and consists of pure-
ly angiogenic vessels, co-opted vessels (i.e. original ves-
sels of an organ incorporated into the growing tumor)
and mosaic vessels. What is more, certain cancers may
develop channels to transport plasma and red cells which
mimic the function of blood vessels but lack endothelial
lining. Those channels may be lined by tumor cells or
be composed of looping matrix structures, and form
anastomoses with blood vessels. This phenomenon,
called vasculogenic mimicry, has been described in a va-
riety of cancers including malignant pheochromocy-
tomas [33]. Therefore, the evaluation of a single pa-
rameter of angiogenesis may be biased.
The participation of mast cells (MCs) in various
pathologic processes gained some interest in the last
years. In particular, MCs are thought to be active stim-
ulators of angiogenesis in cancer. In humans, two pop-
ulations of MCs can be recognized, depending on the
expression of serine proteases stored in their granules.
One population is composed of cells containing only
tryptase while the second contains both tryptase and
chymase. These proteases may exert different biolog-
ical functions: tryptase stimulates endothelial cells pro-
liferation and degrades connective tissue matrix by
activating metalloproteinases and plasminogen activator
with subsequent release of matrix bound VEGF and
FGF-2. Chymase cleaves pro-metalloproteinase 9 (pro-
MMP-9) into active metalloproteinase 9 (MMP-9,
gelatinase B), which is involved in angiogenesis and stro-
mal remodeling. Chymase is also responsible for in-
activation of tissue inhibitor of MMP. Mast cells con-
tribute to angiogenesis not only via degradation of
extracellular matrix. In humans (but not in laborato-
ry animals) chymase generates angiotensin II (AT2)
from angiotensin I. This is thought to be a non-stan-
dard angiotensin converting mechanism, probably im-
portant in pathogenesis of renal and cardiovascular dis-
ease [34]. Angiotensin II is also one of the angiogenic
factors. Activated MCs secrete a wide variety of pro-
angiogenic factors like VEGFs, angiopoietin, basic
fibroblast growth factor (bFGF), transforming growth
factor β (TGF-β), tumor necrosis factor α (TNF-α) and
interleukin 8 (IL-8). Other MCs derived mediators with
angiogenic properties include histamine and heparin
[6, 35, 36].
An association between MCs and neoangiogenesis
has been reported in solid tumors and in hematolog-
ical malignancies. The correlation between the MCs
number and vascular density was observed in breast,
gastric, colorectal, endometrial and oral cancers,
melanomas and non-small cell lung carcinomas [6].
Tryptase-positive MCs count correlated with MVD in
sentinel lymph nodes containing breast cancer mi-
crometastases as well as in early breast cancer [37]. The
number of microvessels was shown to be correlated with
tryptase-positive MCs and rose with the progression
of endometrial carcinoma [38]. The degree of vascu-
larization and both tryptase and chymase-positive MCs
increases parallel to the grade of gastric cancers [39].
In another study on gastric carcinoma, the numbers of
chymase-positive MCs and MVD was significantly in-
creased in undifferentiated tumors [31]. Similarly in
uterine cervix, MVD and density of MCs increases from
normal samples through intraepithelial lesions to in-
vasive carcinoma [41].
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On the other hand, there are studies where no cor-
relation between mast cell density and angiogenesis was
observed. Erol et al. have seen no correlation between
the mast cell count, microvessels density and grade of
endometrial carcinoma [42]. In renal cell carcinoma,
mast cell density was not associated with the tumor sta-
tus such as grade, size, and the number of blood ves-
sels [43]. Renal cell carcinoma may however be a spe-
cial case, as its most frequent variant, clear cell, is
distinctly hypoxia-pathway driven [44].
The extent degree of MCs contribution to angio-
genesis may depend on mast cells subtype and loca-
tion within a tumor. In the central portion of non-small
cell lung carcinoma, a significant correlation between
chymase-positive MCs and MVD was described, while
in the peripheral region the MCs number of both sub-
types correlated with MVD. Nevertheless, the high-
est mast cell count and MVD were observed at the tu-
mor periphery [45, 46].
Most studies suggest that peritumoral mast cells are
more abundant than intratumoral ones; also, intratu-
moral mast cells contain fewer granules. The MCs lo-
cated in different compartments may have different sig-
nificance. In prostate cancer, a high intratumoral count
was indentified as a good prognostic sign, while patients
with a high subcapsular MCs count fare significantly
worse than those with a low one [47]. In our previous
study, we analyzed mast cells in benign nevi, dysplastic
nevi and melanomas and the lowest count of chymase-
positive and tryptase-positive cells were observed in the
melanoma group both intra- and peritumorally [48].
In the present study, mast cells density correlated
with CD31 vessels mainly in the subcapsular region of
pheochromocytomas and there were no significant dif-
ferences between malignant and benign tumors. Ad-
ditionally, tryptase-positive count was inversely cor-
related with mitotic activity and PASS index. These
results may suggest the contribution of the mast cells
to survival of the tumor cells rather than to prolifer-
ation and tumor expansion.
Alternatively, it can be assumed that angiogenic
switch in pheochromocytomas develops rather in
a qualitative than quantitative fashion and expression
of growth factors (VEGF, FGF-2 etc.) is a more reli-
able indicator of angiogenic dependence than MVD
and MCs density [13]. VEGF is expressed not only by
pheochromocytoma cells but also by mast cells, there-
fore comparison of mast cells VEGF expression in ma-
lignant and benign pheochromocytomas would be ra-
tional.
We have also shown an inverse correlation between
MCs count and mitotic activity in the inner tumor area
and tumor periphery. This, along with a negative cor-
relation of PASS index with intratumoral chymase-
positive MCs may support the idea that mast cells may
act as an element of immune surveillance [48]. It is pos-
tulated that mast cells can play a role in inhibition of
tumor growth by a variety of mechanisms: directly, by
induction of apoptosis, decreased cell mobility or in-
creased antitumor inflammatory reaction.
Conclusions
Mast cells may participate in the vessels formation
in pheochromocytoma. We have seen no difference in
angiogenesis or mast cell count between benign and ma-
lignant tumors. Analysis of larger series, especially with
more malignant cases, is needed to elucidate this issue.
This work was partly supported by the Ministry of Ed-
ucation, grant no. N402 684340 awarded to Magdalena
Białas.
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